Biomimetic Lipid-Based Nanosystems for Enhanced Dermal Delivery of Drugs and Bioactive Agents
Source abstract
Abstract
Clinical utility of conventional oral therapies is limited by their inability to deliver therapeutic molecules at the local or targeted site, causing a variety of side effects. Transdermal delivery has made a significant contribution in the management of skin diseases with enhanced therapeutic activities over the past two decades. In the modern era, various biomimetic and biocompatible polymer-lipid hybrid systems have been used to augment the transdermal delivery of therapeutics such as dermal patches, topical gels, iontophoresis, electroporation, sonophoresis, thermal ablation, microneedles, cavitational ultrasound, and nano or microlipid vesicular systems. Nevertheless, the stratum corneum still represents the main barrier to the delivery of vesicles into the skin. Lipid based formulations applied to the skin are at the center of attention and are anticipated to be increasingly functional as the skin offers many advantages for the direction of such systems. Accordingly, this review provides an overview of the development of conventional to advanced biomimetic lipid vesicles for skin delivery of a variety of therapeutics, with special emphasis on recent developments in this field including the development of transferosomes, niosomes, aquasomes, cubosomes, and other new generation lipoidal carriers.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems · Lipid Membrane Structure and Behavior
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Centre for Research in Medical Devices (CÚRAM), Biomedical Sciences Research Building, National University of Ireland Galway, Newcastle, Galway, Ireland
Institute for Stem Cell Biology and Regenerative Medicine, GKVK PO, Bellary Road, Bangalore 560065, India
School of Chemistry, National University of Ireland Galway, Newcastle, Galway, Ireland
Sechenov First Moscow State Medical University, Institute for Regenerative Medicine, Moscow, Russian Federation
References (100+)
Show source-provided references
1. 10.1016/0168-3659(95)00056-E10.1016/0168-3659(95)00056-E ↗
2. 10.1016/S0928-0987(01)00167-110.1016/S0928-0987(01)00167-1 ↗
3. 10.1021/la026585n10.1021/la026585n ↗
4. 10.1016/0168-3659(94)90039-610.1016/0168-3659(94)90039-6 ↗
5. 10.1038/nrd130410.1038/nrd1304 ↗
6. 10.1016/S0169-409X(02)00114-X10.1016/S0169-409X(02)00114-X ↗
7. Kanitakis J. · Eur. J. Dermatol. · 2002 · 12 · 390
8. Scheuplein R. J. · Physiol. Rev. · 1971 · 51 · 70210.1152/physrev.1971.51.4.702 ↗
9. 10.1038/nbt.150410.1038/nbt.1504 ↗
10. 10.1016/S0378-5173(01)00731-110.1016/S0378-5173(01)00731-1 ↗
11. 10.3109/0049825870904394310.3109/00498258709043943 ↗
12. 10.1016/j.addr.2012.09.03110.1016/j.addr.2012.09.031 ↗
13. 10.1016/S0378-5173(03)00183-210.1016/S0378-5173(03)00183-2 ↗
14. 10.1016/j.ijpharm.2005.08.01610.1016/j.ijpharm.2005.08.016 ↗
15. 10.2165/00003495-199345010-0000310.2165/00003495-199345010-00003 ↗
16. 10.1056/NEJM19760923295130510.1056/NEJM197609232951305 ↗
17. 10.1002/jps.102310.1002/jps.1023 ↗
18. 10.1016/S0167-7799(98)01220-710.1016/S0167-7799(98)01220-7 ↗
19. 10.1016/j.trac.2005.07.00610.1016/j.trac.2005.07.006 ↗
20. 10.1080/0898210080246594110.1080/08982100802465941 ↗
21. 10.1021/acs.chemrev.5b0004610.1021/acs.chemrev.5b00046 ↗
22. 10.2217/17435889.4.1.10510.2217/17435889.4.1.105 ↗
23. 10.1016/0039-6257(85)90109-210.1016/0039-6257(85)90109-2 ↗
24. 10.1166/jbn.2008.33410.1166/jbn.2008.334 ↗
25. 10.1023/A:101626802785410.1023/A:1016268027854 ↗
26. 10.1081/PDT-10010202910.1081/PDT-100102029 ↗
27. 10.2147/IJN.S5946310.2147/IJN.S59463 ↗
28. 10.1016/j.ijpharm.2013.06.05210.1016/j.ijpharm.2013.06.052 ↗
29. 10.1016/S0009-3084(98)00062-010.1016/S0009-3084(98)00062-0 ↗
30. 10.1016/j.ejpb.2007.01.02010.1016/j.ejpb.2007.01.020 ↗
31. 10.1503/cmaj.04531610.1503/cmaj.045316 ↗
32. 10.1016/j.jphotobiol.2008.03.00810.1016/j.jphotobiol.2008.03.008 ↗
33. 10.1023/A:101890982104810.1023/A:1018909821048 ↗
34. 10.1016/0378-5173(95)00130-B10.1016/0378-5173(95)00130-B ↗
35. 10.1016/S0378-5173(00)00493-210.1016/S0378-5173(00)00493-2 ↗
36. 10.1016/j.jcis.2016.07.01310.1016/j.jcis.2016.07.013 ↗
37. 10.1016/j.cis.2012.08.00210.1016/j.cis.2012.08.002 ↗
38. 10.1159/00008666610.1159/000086666 ↗
39. 10.1016/j.bpc.2008.01.00810.1016/j.bpc.2008.01.008 ↗
40. 10.1021/la051868b10.1021/la051868b ↗
41. 10.1021/acs.langmuir.5b0411110.1021/acs.langmuir.5b04111 ↗
42. 10.1016/j.intimp.2015.10.02910.1016/j.intimp.2015.10.029 ↗
43. 10.1016/j.ijpharm.2014.10.03110.1016/j.ijpharm.2014.10.031 ↗
44. 10.1016/j.ijpharm.2014.11.01810.1016/j.ijpharm.2014.11.018 ↗
45. 10.3109/10717544.2014.98089610.3109/10717544.2014.980896 ↗
46. 10.3109/08982104.2014.97405810.3109/08982104.2014.974058 ↗
47. 10.1016/j.colsurfb.2014.09.01710.1016/j.colsurfb.2014.09.017 ↗
48. 10.3109/08982104.2014.91131310.3109/08982104.2014.911313 ↗
49. 10.1016/j.ijpharm.2005.02.01610.1016/j.ijpharm.2005.02.016 ↗
50. 10.1081/DDC-12002545810.1081/DDC-120025458 ↗
51. Walve J. R. · Int. J. Appl. Biol. Pharm. Technol. · 2011 · 2 · 204
52. Venkatesh D. N. · Int. J. Res. Pharm. Nano Sci. · 2014 · 3 · 266
53. 10.3109/08982104.2014.95027610.3109/08982104.2014.950276 ↗
54. 10.2147/DDDT.S10312210.2147/DDDT.S103122 ↗
55. 10.3109/08982104.2013.80148910.3109/08982104.2013.801489 ↗
56. 10.1016/j.ejpb.2016.02.01310.1016/j.ejpb.2016.02.013 ↗
57. 10.3109/08982104.2015.109865910.3109/08982104.2015.1098659 ↗
58. 10.1208/s12249-015-0441-710.1208/s12249-015-0441-7 ↗
59. 10.1166/jnn.2015.1046210.1166/jnn.2015.10462 ↗
60. 10.1039/C4CC08746A10.1039/C4CC08746A ↗
61. 10.3389/fphar.2015.0021910.3389/fphar.2015.00219 ↗
62. 10.1016/j.drudis.2016.01.00410.1016/j.drudis.2016.01.004 ↗
63. 10.1155/2014/57467310.1155/2014/574673 ↗
64. 10.1208/ps05043010.1208/ps050430 ↗
65. 10.2174/157016381166614050512592310.2174/1570163811666140505125923 ↗
66. Hundekar Y. R. · World J. Pharm. Pharm. Sci. · 2014 · 5 · 523
67. 10.2147/DDDT.S8637010.2147/DDDT.S86370 ↗
68. 10.12659/MSM.89448410.12659/MSM.894484 ↗
69. Jain S. S. · J. Appl. Pharm. Sci. · 2012 · 02 · 184
70. 10.1016/0142-9612(94)90270-410.1016/0142-9612(94)90270-4 ↗
71. Shahabade G. S. · J. Pharm. Res. · 2009 · 2 · 1174
72. Jadhav S. M. · J. Appl. Pharm. Sci. · 2012 · 02 · 193
73. 10.5402/2012/47483010.5402/2012/474830 ↗
74. Mayer, L.; Shabbits, J.; Bally, M.Enhanced Delivery of Sphingolipids. United States Patent 0031480 A1, Feb 8, 2007.
75. Saraf S. · Int. J. Curr. Sci. Res. · 2011 · 1 · 63
76. 10.1038/243232a010.1038/243232a0 ↗
77. 10.4103/0975-8453.8629010.4103/0975-8453.86290 ↗
78. 10.1080/0193269070178140210.1080/01932690701781402 ↗
79. 10.1016/0009-3084(76)90006-210.1016/0009-3084(76)90006-2 ↗
80. 10.1155/2013/68058010.1155/2013/680580 ↗
81. 10.1016/j.ijpharm.2008.06.02610.1016/j.ijpharm.2008.06.026 ↗
82. Landge A. · Int. J. Pharm. Pharm. Sci. · 2013 · 5 · 314
83. 10.1080/0738-85999122917010.1080/0738-859991229170 ↗
84. 10.3109/0898210090340296210.3109/08982100903402962 ↗
85. 10.1208/s12249-007-9028-210.1208/s12249-007-9028-2 ↗
86. 10.2478/v10007-007-0022-810.2478/v10007-007-0022-8 ↗
87. 10.3923/tmr.2011.101.11510.3923/tmr.2011.101.115 ↗
88. 10.1515/acph-2015-001910.1515/acph-2015-0019 ↗
89. 10.1016/S0169-409X(00)00069-710.1016/S0169-409X(00)00069-7 ↗
90. 10.5897/AJPPX2013.000410.5897/AJPPX2013.0004 ↗
91. 10.1021/jp709582810.1021/jp7095828 ↗
92. Immordino M. L. · Int. J. Nanomed. · 2006 · 1 · 29710.2217/17435889.1.3.297 ↗
93. Gabizon A. A. · Clin. Cancer Res. · 2001 · 7 · 223
94. 10.2174/13892010160415021811265610.2174/138920101604150218112656 ↗
95. 10.1080/1061186070145383610.1080/10611860701453836 ↗
96. 10.3109/08982104.2011.59249510.3109/08982104.2011.592495 ↗
97. 10.1080/1061186070119539510.1080/10611860701195395 ↗
98. Chiechi L. M. · IDrugs · 2004 · 7 · 860
99. 10.2147/IJN.S4690010.2147/IJN.S46900 ↗
100. Zahid S. · J. Drugs Dermatol. · 2008 · 7 · 405